Merck News
Most Popular Merck Story
Merck's diabetes drugs offset Remicade sales decline
Merck ($MRK) managed to beat analyst estimates for fourth-quarter profits and supply slight sales growth of 2%. That's saying something during a quarter when some drugmakers saw profits drop by half Read more...
Latest Headlines
- February 10, 2012
- February 2, 2012
- January 25, 2012
- January 20, 2012
- January 11, 2012
- January 4, 2012
- December 23, 2011
- December 22, 2011
- December 14, 2011
- December 14, 2011
- December 1, 2011
- November 29, 2011
- November 29, 2011
- November 28, 2011
- November 28, 2011
- November 23, 2011
- November 23, 2011
- November 23, 2011
- November 22, 2011
- November 18, 2011
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
